ライフサイエンスコーパス: pharmacokinetics

1 posure increased with dose, with time-linear pharmacokinetics.

2 -MRI), and computed correlates of crolibulin pharmacokinetics.

3 effects, low bioavailability, or undesirable pharmacokinetics.

4 The primary outcomes were safety and pharmacokinetics.

5 ma and islatravir-triphosphate intracellular pharmacokinetics.

6 ic insight into underlying phenomena in skin pharmacokinetics.

7 ses may play a role in the viremia-dependent pharmacokinetics.

8 Drug transporters play a crucial role in pharmacokinetics.

9 sensitized cynomolgus monkeys with favorable pharmacokinetics.

10 compounds that might interact with clozapine pharmacokinetics.

11 in to enable multifactorial analysis of skin pharmacokinetics.

12 ct as a real-time assay of antiplatelet drug pharmacokinetics.

13 formulated drugs and play key roles in their pharmacokinetics.

14 oor bioavailability and undetectable in vivo pharmacokinetics.

15 ptor agonist fentanyl and characterized MCAM pharmacokinetics.

16 on resulting in dose-dependent and nonlinear pharmacokinetics.

17 esian estimates of plasma and intrapulmonary pharmacokinetics.

18 Secondary outcomes show no detriment to ATRA pharmacokinetics..

19 assess the role of polymorphisms in digoxin pharmacokinetics accurately.

20 n of each drug pair, we enabled uniform drug pharmacokinetics across the drug combinations, thus allo

21 erent CO release kinetics and examined their pharmacokinetics after administration via oral, intraper

22 We assessed MA and OA pharmacokinetics after ingestion of olive oils (OOs) wit

23 e preclinical evaluation of LSPD in terms of pharmacokinetics, ammonia uptake, and toxicology to seek

24 To determine the pharmacokinetics and -dynamics of ciprofloxacin prophyla

25 ally relevant TLR7 antagonist with favorable pharmacokinetics and 70.8% oral bioavailability in mice.

26 mAb114 has linear pharmacokinetics and a half-life of 24.2 days (standard

27 ns is complicated by the disparities in drug pharmacokinetics and activity.

28 ynergy with first-line drugs in macrophages, pharmacokinetics and adjunctive bactericidal activity, a

29 c variants associated with immunosuppressant pharmacokinetics and adverse outcomes.

30 relationship was observed between pimodivir pharmacokinetics and age.

31 ion assays with human cells in vitro and IgE pharmacokinetics and anaphylaxis experiments in vivo.

32 olerated dose; secondary objectives included pharmacokinetics and antitumor activity; exploratory obj

33 as well as child-specific factors including pharmacokinetics and appropriate formulations.

34 candidates were evaluated for their in vivo pharmacokinetics and biodistribution in rats.

35 ernalization, low cytotoxicity, controllable pharmacokinetics and biodistribution, have shown promisi

36 werful analytical tool for the assessment of pharmacokinetics and biomarkers in drug development.

37 ds out of cells, and has major roles in drug pharmacokinetics and cancer multidrug resistance.

38 possible effects of cebranopadol on cocaine pharmacokinetics and cocaine-induced hyperactivity for t

39 agents in this spectral range impedes their pharmacokinetics and decreases their thermal stability,

40 The pharmacokinetics and distribution of h-alpha-Gal A mRNA

41 Pharmacokinetics and dose-limiting toxicities were used

42 Our daily rhythms also regulate the pharmacokinetics and efficacy of several therapeutics.

43 The pharmacokinetics and efficacy of these ADCs were further

44 ans and white Americans, are known to affect pharmacokinetics and efficacy of tramadol, morphine, and

45 ycoprotein efflux on bumped kinase inhibitor pharmacokinetics and efficacy.

46 avenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in p

47 Primary outcomes were safety, pharmacokinetics and imaging feasilibity of ONM-100.

48 The pharmacokinetics and in vivo oral efficacy of compound 1

49 Plasma islatravir pharmacokinetics and intracellular islatravir-triphospha

50 Despite evidence that RYGB alters alcohol pharmacokinetics and is associated with an increased ris

51 cilitates better understanding of (18)F-FGln pharmacokinetics and may be necessary for response asses

52 ese data provide insights for evaluating the pharmacokinetics and normal -tissue toxicity and in dete

53 To determine the pharmacokinetics and pharmacodynamics (PKPD) of ciproflo

54 Nevertheless, insights into the pharmacokinetics and pharmacodynamics of LAmB continue t

55 ed on tissue extracts to analyze the in vivo pharmacokinetics and pharmacodynamics relationship of KD

56 values at time of IFE were estimated through pharmacokinetics and pharmacodynamics simulation, IFE ou

57 Recent clinical data on vancomycin pharmacokinetics and pharmacodynamics suggest a reevalua

58 We compare the pharmacokinetics and pharmacodynamics to the clinical co

59 2/CD25 fusion protein, with greatly improved pharmacokinetics and pharmacodynamics when compared with

60 mework combines viral dynamics with antibody pharmacokinetics and pharmacodynamics, and will be gener

61 the mode of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, clinical indicati

62 these limitations and improving bacteriocin pharmacokinetics and pharmacodynamics.

63 The model accounts for drug pharmacokinetics and pharmacodynamics.

64 water, in a regimen recapitulating clinical pharmacokinetics and pharmacodynamics.

65 culosis, the nanoparticles provided improved pharmacokinetics and pharmacodynamics.

66 ver study was used to assess plasma nicotine pharmacokinetics and product liking for two e-cigarettes

67 pertzian tumor growth with antibody-mediated pharmacokinetics and radiation-induced cell killing.

68 discovered as a 5-HT(2C)R PAM with improved pharmacokinetics and reduced off-target interactions rel

69 xtrapolation for better predictions of human pharmacokinetics and risk of DDIs.

70 We aimed to assess the terminal phase pharmacokinetics and safety of long-acting injectable ca

71 Viral load (VL), disease severity, pharmacokinetics and safety were assessed until discharg

72 every 12 h for 15 days in part A (to assess pharmacokinetics and safety) and for 24 weeks in part B

73 iver and therefore a determinant of clinical pharmacokinetics and site of drug-drug interactions.

74 The pharmacokinetics and targeting capacity of selected lead

75 Methods: To explore their pharmacokinetics and the role of the immune cells, BiTE

76 Together with promising pharmacokinetics and toxicology profiles, these results

77 e dependence treatment may alter the cocaine pharmacokinetics and/or attenuate cocaine-induced reward

78 ffects through variable drug concentrations (pharmacokinetics) and drug actions (pharmacodynamics), a

79 We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dap

80 , placebo-controlled trial to assess safety, pharmacokinetics, and acceptability of a tenofovir disop

81 We aimed to evaluate the safety, pharmacokinetics, and activity of atezolizumab in childr

82 We aimed to characterize the safety, pharmacokinetics, and antimalarial activity of a tablet

83 study, we aimed to assess islatravir safety, pharmacokinetics, and antiretroviral activity in treatme

84 onoclonal antibody, to determine its safety, pharmacokinetics, and antitumour activity in children an

85 In part 2, we have evaluated the safety, pharmacokinetics, and antiviral activity of multiple dos

86 hase 2 clinical study evaluating the safety, pharmacokinetics, and antiviral activity of UB-421 monot

87 kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravt

88 addition, H-Dots can monitor targetability, pharmacokinetics, and drug delivery, while also showing

89 of our knowledge, this is the first time MA pharmacokinetics, and effects on endothelial function in

90 Safety, pharmacokinetics, and efficacy of GSK2838232 boosted by

91 dly impacts on their in vivo immunogenicity, pharmacokinetics, and functional attributes.

92 9 were well tolerated, showed dose-dependent pharmacokinetics, and had potent antiviral activity in p

93 udy to evaluate mAb114 safety, tolerability, pharmacokinetics, and immunogenicity.

94 nfluence recognition of the intended target, pharmacokinetics, and off-target effects.

95 rolled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-C

96 tudy investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of iscalimab in h

97 The safety, pharmacokinetics, and pharmacodynamics of MMV390048 supp

98 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses

99 assessed the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of treatment with

100 surgery can influence absorption, excretion, pharmacokinetics, and pharmacodynamics of various antico

101 ss safety, tolerability, antitumor efficacy, pharmacokinetics, and pharmacodynamics.

102 um tolerated dose, recommended phase 2 dose, pharmacokinetics, and preliminary clinical activity of r

103 to determine safety, tracer biodistribution, pharmacokinetics, and radiation dosimetry.

104 provements in efficacy, metabolic stability, pharmacokinetics, and safety profiles.

105 Viral load, influenza symptoms, pharmacokinetics, and safety were evaluated.

106 alterations that can influence antimicrobial pharmacokinetics, and significant interpatient variabili

107 These properties, suitable pharmacokinetics, and the lack of cross-resistance resul

108 ssover sequence to evaluate biodistribution, pharmacokinetics, and tumor and organ dosimetry.

109 ithout HIV, we aimed to characterise safety, pharmacokinetics, and virological suppression in adults

110 mAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, ma

111 s were evaluation of safety/tolerability and pharmacokinetics; antitumor activity was a secondary obj

112 ever, dye instability, aggregation, and poor pharmacokinetics are current drawbacks that limit perfor

113 gp (C1236T, G2677T/A, and C3435T) on digoxin pharmacokinetics are inconclusive.

114 Safety profiles and pharmacokinetics are suitable for PET imaging, and absor

115 cation of radiotracers in understanding drug pharmacokinetics as well as the local biology at the inf

116 assessed by incidence of adverse events) and pharmacokinetics (assessed by serum atezolizumab concent

117 ade 3 or higher) and dolutegravir population pharmacokinetics, assessed in participants who began rif

118 The pharmacokinetics associated with these 4 chelator-linker

119 ghts the importance of investigating MoA and pharmacokinetics at an early stage for phenotypically ac

120 es in cycles 1 and 2 and provided a pre-dose pharmacokinetics blood sample on day 1 of cycle 3.

121 r release kinetics have been able to improve pharmacokinetics but are not ideal for drugs with short

122 Misspecification of pharmacokinetics can lead to wrongly predicted timing or

123 the direct observation and quantification of pharmacokinetics, can be used to glean mechanistic insig

124 electivity, developability, and in vivo oral pharmacokinetics characterize these tools, which we hope

125 the mode of action, antimicrobial activity, pharmacokinetics, clinical indications, and safety profi

126 s on the mode of action, antiviral activity, pharmacokinetics, clinical indications, and safety profi

127 mg twice daily versus warfarin on population pharmacokinetics, D-dimer, prothrombin fragment 1 + 2 (P

128 tic ductal adenocarcinoma is limited by poor pharmacokinetics, dense fibrosis and hypo-vascularizatio

129 Plasma or intrapulmonary pharmacokinetics did not predict clinical treatment resp

130 bel-free applications of drug metabolism and pharmacokinetics (DMPK) analysis and high-throughput scr

131 rate and shows excellent drug metabolism and pharmacokinetics (DMPK) properties with significant brai

132 riCa study, which was designed to assess the pharmacokinetics, efficacy, and safety of the fixed-dose

133 ld and analyze a compartmental model of lead pharmacokinetics, focused specifically on addressing neu

134 (203)Pb-L1-(203)Pb-L5 demonstrated favorable pharmacokinetics for (212)Pb-based TRT.

135 Pharmacokinetics for CLR 131 were extrapolated to adult

136 models) were used to perform simulations of pharmacokinetics for different combinations of perfusion

137 selective CSF1R inhibitor, showed favorable pharmacokinetics for inhalational treatment and intranas

138 phase 1 dose-escalation study, the clinical pharmacokinetics for PT2977 supports the hypothesis that

139 us administration (20 mug/kg), and sustained pharmacokinetics for up to 72 h.

140 Safety, pharmacokinetics, forced expiratory volume in 1 second,

141 istinguish direct acidotic effects on tracer pharmacokinetics from acidosis-induced hypocontractility

142 Pharmacokinetics-guided lead optimization resulted in th

143 scanning to assess whether in vivo (18)F-FDG pharmacokinetics has added value over static PET to dist

144 ODDA-PTX shows differentiated pharmacokinetics, higher maximum tolerated doses and inc

145 ncorporated VRC01 neutralization using serum pharmacokinetics (HVTN 104) and in vitro pharmacodynamic

146 Secondary objectives included evaluation of pharmacokinetics, immunogenicity, and efficacy.

147 The secondary end point was HTT(Rx) pharmacokinetics in cerebrospinal fluid (CSF).

148 less than 25 kg, we assessed dolutegravir's pharmacokinetics in children given once daily 25 mg film

149 s had no direct effect on [(64)Cu][Cu(ATSM)] pharmacokinetics in either normoxic or hypoxic hearts, b

150 e primary objective was to compare pimodivir pharmacokinetics in elderly (aged 65-85 years) versus no

151 tolerated and demonstrated dose-proportional pharmacokinetics in healthy participants in part 1 of it

152 We investigated dolutegravir population pharmacokinetics in maternal plasma, cord, breastmilk an

153 rk enabled enhanced FAP binding and improved pharmacokinetics in most of the derivatives, resulting i

154 nsing technologies, capable of tracking drug pharmacokinetics in noninvasively retrievable biofluids

155 f Doxebo before Doxil did not impact Doxil's pharmacokinetics in plasma and therefore does not cause

156 ieves >7-day gastric retention and sustained pharmacokinetics in the challenging dog model.

157 VID-19) patients, without information on the pharmacokinetics in this population.

158 ives: To characterize rifapentine population pharmacokinetics, including autoinduction, and determine

159 e gaps, test potential solutions using human pharmacokinetics informed through preclinical infection

160 rugs, and many candidates failed due to poor pharmacokinetics, interspecies differences, and adverse

161 derstanding of renal physiology and diuretic pharmacokinetics is essential for skillful use of diuret

162 g lipid hydrophobicity, structure, and siRNA pharmacokinetics is unclear.

163 measure antibody biodistribution and tissue pharmacokinetics is well established, but current PET sy

164 ts with grade 2 or worse adverse events, and pharmacokinetics, measured by apparent terminal phase ha

165 ncept, we conducted the first-ever extensive pharmacokinetics measurement of mAb in major tissues wit

166 ods: P2X7 receptor affinity and specificity, pharmacokinetics, metabolic stability, blood-brain barri

167 conducted a systematic investigation of THC pharmacokinetics, metabolism and distribution in blood a

168 ulated using previously published population pharmacokinetics model at dose 10-40 mg/kg for weight-ba

169 netic samples were assessed using population pharmacokinetics modeling.

170 Integration with pharmacokinetics modelling principles through a web inte

171 In pharmacokinetics, modifications that increase plasma hal

172 amma-detection apparatus to characterize the pharmacokinetics of (99m)Tc-sestamibi and (99m)Tc-NOET i

173 In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin

174 The pharmacokinetics of a deuterated compound depends on the

175 Here, we report the pharmacokinetics of a novel PET radioligand, (18)F-LSN33

176 The pharmacokinetics of bictegravir and its association with

177 The pharmacokinetics of citric acid and 1,2-dipalmitoyl-sn-g

178 The safety profile, the linear pharmacokinetics of citric acid following repeated admin

179 cebranopadol did not significantly alter the pharmacokinetics of cocaine.

180 In this study, we evaluated the pharmacokinetics of commonly administered antimicrobials

181 t in silico model to predict the intravenous pharmacokinetics of dendrimers, a commonly explored drug

182 istration of efavirenz and rifampicin on the pharmacokinetics of depot medroxyprogesterone acetate (D

183 in vitro models that match the physiological pharmacokinetics of drug exposure.

184 The primary endpoint was pharmacokinetics of DTG in women and breastfed infants;

185 vestigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women

186 One approach is to improve the pharmacokinetics of existing or novel venom-derived pept

187 is required to understand the intrapulmonary pharmacokinetics of first-line anti-tuberculosis drugs.

188 al decitabine plus cedazuridine emulated the pharmacokinetics of intravenous decitabine, with a simil

189 To date, pharmacokinetics of maslinic (MA) and oleanolic (OA) aci

190 The pharmacokinetics of ML290 in mice demonstrated its high

191 cted to assess the safety, tolerability, and pharmacokinetics of MP0250 in 45 patients with advanced

192 The pharmacokinetics of nanoparticle-borne drugs targeting t

193 y investigated the safety, tolerability, and pharmacokinetics of nilotinib, and measured biomarkers i

194 Further research should consider the pharmacokinetics of non-steroidal anti-inflammatory drug

195 pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cispla

196 Effects of different genotypes on the pharmacokinetics of probe substrates may support their u

197 ed to describe the plasma and intrapulmonary pharmacokinetics of rifampicin, isoniazid, pyrazinamide,

198 termination of recommended phase 2 dose, and pharmacokinetics of rogaratinib.

199 rHuPH20's impact on the systemic pharmacokinetics of several mAbs has been previously des

200 Data are lacking on the safety and pharmacokinetics of single-dose BIVV001.

201 great potential for real-time monitoring of pharmacokinetics of small molecules associated with live

202 Two experiments were conducted to study the pharmacokinetics of stereoisomers of all-rac-alpha-tocop

203 etics and biocompatibility, and the superior pharmacokinetics of tetrazine-functionalised SWCNTs coul

204 Pharmacokinetics of the 3HP regimen were measured.

205 Pharmacokinetics of the antiretrovirals and DAAs were ch

206 lease metabolites that alter the 'canonical' pharmacokinetics of the drug.

207 -conjugated polyethylene glycol improves the pharmacokinetics of the dual-hormone therapy and enhance

208 The pharmacokinetics of these BiNPs can be easily improved v

209 en though there are known sex differences in pharmacokinetics of these drugs.

210 The investigation of the pharmacokinetics of these radiopharmaceuticals in vivo i

211 We investigate the pharmacokinetics of this conjugate in mice and show that

212 We aimed to assess the safety and pharmacokinetics of this intravaginal ring over 90 days

213 ssessed the safety, side-effect profile, and pharmacokinetics of TY014, a fully human IgG1 anti-yello

214 flux pumps that are strongly involved in the pharmacokinetics of various drugs and nutrient distribut

215 potential effects of cebranopadol on cocaine pharmacokinetics or cocaine-induced hyperactivity.

216 Radiation dosimetry calculations determined pharmacokinetics parameters and absorbed alpha-emission

217 healthy humans for safety, tolerability, and pharmacokinetics paved the way for its further developme

218 relies on accurately estimating the correct pharmacokinetics, pharmacodynamics, and drug interaction

219 We assessed the safety, pharmacokinetics, pharmacodynamics, and efficacy of luma

220 nd for 24 weeks in part B (to assess safety, pharmacokinetics, pharmacodynamics, and efficacy).

221 We report the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary effi

222 In this article, we review the clinical pharmacokinetics, pharmacodynamics, safety, and efficacy

223 Recent data on polymyxin pharmacokinetics, pharmacodynamics, toxicity, and clinic

224 Pharmacokinetics-pharmacodynamics data show a steady-sta

225 rent modeling strategies, such as population pharmacokinetics/pharmacodynamics (PK/PD) and systems bi

226 clinical evaluation, including a comparative pharmacokinetics/pharmacodynamics study that is usually

227 a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics.

228 sive bioanalytical characterization of their pharmacokinetics (PK) and catabolism in both preclinical

229 n factor EWS-FLI1 in Ewing sarcoma, but poor pharmacokinetics (PK) and toxicity limit its clinical us

230 , the lack of reliable data on antimicrobial pharmacokinetics (PK) at infection sites hinders efforts

231 frequency to bimonthly injections, variable pharmacokinetics (PK) between patients and various adver

232 Here, plasma pharmacokinetics (PK) data of the OPTILIV trial in which

233 Improved in vivo pharmacokinetics (PK) for the cabazitaxel (CBTX) NDCs wi

234 beta-cyclodextrin (betaCAB) and examined the pharmacokinetics (PK) in Sprague-Dawley rats for 3 month

235 0 service personnel were determined, and the pharmacokinetics (PK) of a 30-mg oral dose of PQ was mea

236 of this study was to characterize the plasma pharmacokinetics (PK) of cannabinoids and their metaboli

237 We describe the pharmacokinetics (PK) of dolutegravir (DTG) 50 mg once d

238 The pharmacokinetics (PK) of endothelial surface-targeted af

239 Compound 6f also demonstrated excellent pharmacokinetics (PK) profile (high oral bioavailability

240 es 13, 29, 32, 43, and 51 showed a favorable pharmacokinetics (PK) profile across different species a

241 her coagulation proteases, and a preclinical pharmacokinetics (PK) profile consistent with bid dosing

242 This pharmacokinetics (PK) study assessed DMPA among HIV/TB c

243 t microbiome can alter drug disposition, the pharmacokinetics (PK), and biodistribution of acetaminop

244 date by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for p

245 munoglobulin (IVIg) on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the

246 ients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and prelim

247 This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), clinical e

248 he relationship between drug concentrations (pharmacokinetics, PK), including in breastmilk, and impa

249 Analyses of drug pharmacokinetics (PKs) and pharmacodynamics (PDs) perfor

250 bioactive compounds, positively influencing pharmacokinetics, potency and conformation.

251 inical candidate, MDI-2268, having excellent pharmacokinetics, potent activity against vitronectin-bo

252 ding at least one dose of pegilodecakin, and pharmacokinetics (previously published).

253 t promising drug-like candidate, with a good pharmacokinetics profile in vivo.

254 etastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bi

255 nolics were evaluated by their molecular and pharmacokinetics properties and disease association netw

256 ysicochemical as well as drug metabolism and pharmacokinetics properties and finally in vivo proof-of

257 Compound 48c showed good pharmacokinetics properties in mice via intraperitoneal

258 dual domains lack sufficient potency and the pharmacokinetics properties that are required for in viv

259 was restricted by variable and dose-limited pharmacokinetics resulting from extensive metabolism of

260 for administration, and poor selectivity and pharmacokinetics resulting in off-target toxicity and in

261 ide) of quercetin found in human plasma, the pharmacokinetics results have demonstrated an increased

262 urrently available iron chelators, including pharmacokinetics, routes of administration, and adverse

263 ug interactions (DDIs) leading to changes in pharmacokinetics, safety and efficacy.

264 This phase 1b study evaluated the pharmacokinetics, safety, and antiviral effects of the r

265 Further exploration of the pharmacokinetics, safety, and efficacy in children and p

266 Purpose To evaluate the pharmacokinetics, safety, and efficacy of vandetanib-elu

267 We characterised the pharmacokinetics, safety, and optimal dose of linezolid

268 We demonstrate favourable pharmacokinetics, safety, tolerability, dose-dependent P

269 ity and the potential to greatly improve the pharmacokinetics, stability, and downstream developabili

270 xtures, these were found to have sub-optimal pharmacokinetics, stability, tolerability and/or efficac

271 We obtained descriptive safety and pharmacokinetics statistics, and estimated efficacy resu

272 In vivo pharmacokinetics studies on 10 revealed slow absorption,

273 earance and poor oral bioavailability in its pharmacokinetics studies.

274 This pharmacokinetics study assessed DMPA among HIV/TB co-inf

275 Pharmacokinetics study demonstrated adipoRon (APN recept

276 Ultimately, a preliminary oral pharmacokinetics study in male beagles showed that 28 is

277 osslinked Rososome with better stability and pharmacokinetics than its non-crosslinked counterpart.

278 matologists with less consideration of their pharmacokinetics than that of conventional synthetic DMA

279 based excipients to yield a formulation with pharmacokinetics that is faster than the currently avail

280 first summarize the literature on gold salt pharmacokinetics, therapeutic effects, adverse reactions

281 that aim to follow and quantify topical drug pharmacokinetics, these tools can come with limitations,

282 mized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse m

283 bitor with oral bioavailability and suitable pharmacokinetics to ameliorate cardiac and renal stress-

284 hich are safe, excretable and have favorable pharmacokinetics to efficiently deliver and retain radio

285 xtends phase 0 benefits beyond assessment of pharmacokinetics to include understanding of mechanism o

286 able metronomic low-dose chemotherapy and IP pharmacokinetics using biodegradable nanotextile implant

287 PPGL can be achieved by assessing (18)F-FDG pharmacokinetics using dynamic PET/CT scanning.

288 ionship between SNP combinations and digoxin pharmacokinetics was explored via a population pharmacok

289 cs and intracellular islatravir-triphosphate pharmacokinetics were approximately dose proportional.

290 Safety and pharmacokinetics were consistent with the well character

291 Rifapentine population pharmacokinetics were described successfully with a one-

292 tion, as well as improvements in potency and pharmacokinetics were desirable for discovering pipeline

293 ADx-001 pharmacokinetics were determined in monkeys and its tiss

294 Cardiac [(64)Cu][Cu(ATSM)] pharmacokinetics were determined using NaI detectors, wi

295 Pharmacokinetics were dose proportional and exceeded pre

296 Anetumab ravtansine pharmacokinetics were dose proportional; the average hal

297 Pharmacokinetics were highly variable among subjects and

298 DSTP3086S pharmacokinetics were linear.

299 Intestinal and systemic pharmacokinetics were measured in six patients with Croh

300 ss than 40 kg, we also assessed dolutegravir pharmacokinetics within-subject on film-coated tablet do